

Exposing WHO Conflicts of Interest

Capturing Global Health by Subversion

The GLObal Public Private Partnership

Policy Makers

This is the part of the GPPP where policy originates

B.I.S.

Bank for International Settlements (B.I.S.)

They ultimately control the money supply and thus global markets, trade and national economies.

Central Banks

Central Banks (Coordinated by the B.I.S.)

They are "going direct" and directly funding government spending. Monetary policy has effectively become fiscal policy.

W.E.F.

C.F.R.

Club of Rome

Chatham House

Rockefeller

Think Tanks & Global Representative Groups

These formulate the policies to achieve GPPP objectives. Resource allocation determined by the B.I.S. and Central Banks but they work in "partnership" with the think tanks and the representative bodies to convert that into global political policy.

Policy Distributers

United Nations

IMF

I.P.C.C

World Bank

W.H.O

Philanthropists

Global Corp's

N.G.O

These organisations and bodies take policy directives from the policy makers and distribute them to the policy enforcers.

Policy Enforcers

National Governments

Civil Service, NHS, RRU, IPSO, Ofcom, Police, Military, Courts, Local Governments, Statutory Agencies etc.

Selected Scientific Authorities

SAGE, NERVTAG, ICL, MHRA, JCVI etc.

The Policy Enforcers exploit or work with the Selected Scientific Authorities to justify the policies they are required to enforce.

Policy Propagandists

Propagandists and Hybrid Warfare Specialists

M.S.M, Fact Checkers (Politifact, Full Fact etc.), Social Media Platforms, Hybrid Warriors (77th Brigade, Huteighteen etc.), Anti-Hate Campaigners (CCE, CCDH etc)

The propagandists and hybrid warfare specialists are tasked with convincing the public to accept and hopefully believe in the policies. They use psychological manipulation, disinformation, misinformation, censorship and propaganda.

Policy Subjects

The Public

We are the subjects of the policy which cascades down through the GPP system. We largely pay for the system through taxation and public borrowing. The system is designed to exploit us but we are an increasingly unnecessary component as the GPPP look to seize the global commons.

The Rulers of the World



The Rothschild Investment Corp. and the Edmond De Rothschild Holdings


Big Media


News Corp,
Disney,
Comcast
Time Warner
The New York Times

are the two largest stakeholders in Vanguard and Blackrock


Vanguard®
\$7.50 trillion

\$2,080 trillion

Rothschild & Co

EDMOND DE ROTHSCHILD

BlackRock®
\$9.2 trillion

Orsini family (Italy), Bush family (USA), the British Royal family, the Morgans, Vanderbilts du Pont family and Rockefellers
Are all owners of Vanguard and BlackRock

Pfizer
Johnson & Johnson
AstraZeneca
Merck
GlaxoSmithKline

Big Pharma

BlackRock and Vanguard form a secret monopoly, combined ownership encompasses nearly 90% of all S&P 500 firms.

Control of Big Pharma

BlackRock®

Vanguard®


STATE STREET®

Top Institutional Share Holders

Total: \$9.2 trillion

<https://www.holdingschannel.com/all/stocks-held-by-blackrock-inc/>

Holder	Shares	Value (\$)
Vanguard Group, Inc.	12,124,607	10,608,667,386
Blackrock Inc.	9,903,465	8,665,234,771
State Street Corporation	6,362,736	5,567,203,117
Bank of America Corporation	5,839,903	5,109,739,927
FMR, LLC	3,892,865	3,406,140,089
JP Morgan Chase & Company	2,542,122	2,224,280,486
CARLYLE GROUP INC	7,764,706	360,904
TWITTER INC		3,626,098
JOHNSON & JOHNSON	191,385,110	31,528,781
PFIZER INC	407,048,272	15,940,011
MRNA / Moderna Inc	19,390,725	4,556,434,000
ASTRAZENECA PLC	8,174,7	489,668
BIONTECH SE	1,481,390	331,654
NOVAVAX INC		970,594
SANOFI	14,538,448	765,593
MERCK & CO INC	187,155,493	14,555,084
ELI LILLY & CO	60,927,657	13,984,117
GILEAD SCIENCES INC	123,804,538	8,525,183
BRISTOL MYERS SQUIBB CO	175,100,707	11,700,230
BIOGEN INC	13,206,591	4,573,047
ILLUMINA INC		5,314,852



Vanguard®

Vanguard High Dividend Yield Index Fund

[Stock holdings](#) | [Bond holdings](#) | [Short-term reserve holdings](#)









































as of: 08/31/2021

Stock Holdings			Total: \$7.50 trillion
Holding	Shares	Market Value	
Johnson & Johnson	9,724,171	\$1,683,545,725	
Pfizer Inc.	20,595,438	\$948,831,829	
Merck & Co. Inc.	9,346,496	\$713,044,180	
Gilead Sciences Inc.	4,634,044	\$337,265,722	
Eli Lilly & Co.	3,127,195	\$807,723,197	
Bristol-Myers Squibb Co.	8,241,776	\$551,045,143	
Comcast Corp. Class A	16,825,781	\$1,020,988,391	
Carlyle Group Inc.	595,138	\$29,387,914	
AT&T Inc.	26,355,223	\$722,660,215	
Citigroup Inc.	7,625,547	\$548,353,085	
Bank of America Corp.	27,833,088	\$1,162,031,424	
Carlyle Group Inc.	595,138	\$29,387,914	
BlackRock Inc.	427,258	\$403,028,199	

State Street Corp - Latest 13F Holdings, Performance, AUM

Market Value - \$2.81 trillion

STATE STREET®

File Date	Form	Security		Prev Shares		Current Shares	
2021-09-10	13G	ALT / Altimmune Inc	 	3,991,141			
2021-06-30	13F	PFE / Pfizer Inc.	 	278,568,311	1.34	10,908,735	9.53
2021-06-30	13F	JNJ / Johnson & Johnson	 	142,047,884	1.27	23,400,968	1.51
2021-06-30	13F	AZN / AstraZeneca Plc	 	239,870	-17.45	14,368	-0.55
2021-06-30	13F	MRNA / Moderna Inc	 	7,325,576	21.91	1,721,364	118.76
2021-06-30	13F	NVAX / Novavax, Inc.	 	1,693,390	17.44	359,524	37.52
2021-06-30	13F	INO / Inovio Pharmaceuticals	 	8,907,158	7.89	82,569	7.78
2021-06-30	13F	MRK / Merck & Co., Inc.	 	114,073,945	1.23	8,943,537	2.11
2021-06-30	13F	GSK / GlaxoSmithKline plc	 	9,163,297	-2.25	369,759	8.62
2021-06-30	13F	LLY / Eli Lilly And Co	 	32,927,576	1.30	7,557,537	24.45
2021-02-16	13G/A	MYGN / Myriad Genetics, Inc.		3,715,530			
2021-06-30	13F	NVS / Novartis AG	 	2,039,489	1.63	186,083	8.48
2021-06-30	13F	BIO / Bio-Rad Laboratories, Inc.	 	974,441	0.28	627,823	13.12
2021-06-30	13F	PKI / PerkinElmer, Inc.	 	4,435,573	1.47	684,897	22.13
2021-06-30	13F	BMJ / Bristol-Myers Squibb Co	 	92,145,348	1.32	6,157,152	6.42
2021-06-30	13F	ILMN / Illumina, Inc.	 	5,869,364	1.77	2,777,442	25.39
2021-06-30	13F	ABT / Abbott Laboratories	 	71,745,046	1.73	8,317,403	-1.59
2021-06-30	13F	NYT / New York Times Co	 	3,808,484	8.59	165,859	-6.58
2021-06-30	13F	BRK.A / Berkshire Hathaway, Inc.	 	192	-9.43	80,371	-1.71
2021-06-30	13F	BRK.B / Berkshire Hathaway,	 	78,524,981	0.03	21,823,663	8.82
2021-06-30	13F	BNDX / Vanguard Total International Bond Index Fund	 	308,072	38.75	17,591	38.71

Covid
Vaccine
CandidateCovid
Auxiliary
IndustryCovid
Investments

BlackRock®



Influence

South Africa

Holding	Description	Market Value USD	% of Net Assets
South Africa			
54,594	Absa Group Ltd	469,546	0.08
7,801	African Rainbow Minerals Ltd	147,480	0.02
4,016	Anglo American Platinum Ltd^	591,927	0.09
32,073	AngloGold Ashanti Ltd^	693,991	0.11
28,514	Aspen Pharmacare Holdings Ltd	277,488	0.04
25,509	Bid Corp Ltd	493,829	0.08
21,249	Bidvest Group Ltd	245,195	0.04
5,543	Capitec Bank Holdings Ltd^	532,015	0.09
18,388	Clicks Group Ltd	300,771	0.05
29,510	Discovery Ltd^	265,298	0.04
22,033	Exxaro Resources Ltd	260,852	0.04
356,603	FirstRand Ltd^	1,249,756	0.20
68,538	Gold Fields Ltd	636,215	0.10
278,554	Growthpoint Properties Ltd (REIT)	249,951	0.04
38,221	Harmony Gold Mining Co Ltd	163,872	0.03
59,694	Impala Platinum Holdings Ltd^	1,110,623	0.18
4,978	Kumba Iron Ore Ltd^	206,007	0.03
19,742	Mr Price Group Ltd	259,171	0.04
126,928	MTN Group	750,845	0.12
32,511	MultiChoice Group	285,430	0.05
33,020	Naspers Ltd 'N'	7,854,606	1.26
27,319	Nedbank Group Ltd	260,179	0.04
26,993	Northam Platinum Ltd	474,280	0.08
380,042	Old Mutual Ltd^	325,318	0.05

Holding	Description	Market Value USD	% of Net Assets
South Africa continued			
60,352	Rand Merchant Investment Holdings Ltd	125,885	0.02
40,363	Remgro Ltd	285,155	0.05
138,067	Sanlam Ltd^	554,839	0.09
41,391	Sasol Ltd	600,112	0.10
38,475	Shoprite Holdings Ltd	411,555	0.07
207,367	Sibanye Stillwater Ltd	919,837	0.15
14,387	SPAR Group Ltd	185,607	0.03
101,197	Standard Bank Group Ltd	864,265	0.14
10,870	Tiger Brands Ltd	154,630	0.02
47,870	Vodacom Group Ltd^	409,089	0.07
74,507	Woolworths Holdings Ltd	251,985	0.04
		22,867,604	3.68

Banking	Retail
Mining	
Pharmaceutical	
Insurance	
Mobile	
Media	

Holding	Description	Market Value USD	% of Net Assets
South Africa			
USD 4,300,000	Eskom Holdings SOC Ltd RegS 6.75% 6/8/2023	4,448,103	0.11
USD 5,100,000	Eskom Holdings SOC Ltd RegS 7.125% 11/2/2025 ^A	5,277,589	0.13
USD 4,175,000	Eskom Holdings SOC Ltd RegS 6.35% 10/8/2028	4,430,066	0.11
USD 1,800,000	Eskom Holdings SOC Ltd RegS 8.45% 10/8/2028 ^A	1,965,560	0.05
USD 4,050,000	Republic of South Africa Government International Bond 5.875% 30/5/2022 ^A	4,269,368	0.11
USD 5,800,000	Republic of South Africa Government International Bond 4.665% 17/1/2024	6,156,120	0.15
USD 8,450,000	Republic of South Africa Government International Bond 5.875% 16/9/2025 ^A	9,330,215	0.23
USD 5,150,000	Republic of South Africa Government International Bond 4.875% 14/4/2026	5,415,276	0.13
USD 3,900,000	Republic of South Africa Government International Bond 4.85% 27/9/2027	4,039,328	0.10
USD 8,050,000	Republic of South Africa Government International Bond 4.30% 12/10/2028	7,931,403	0.20

Holding	Description	Market Value USD	% of Net Assets
USD 8,650,000	Republic of South Africa Government International Bond 4.85% 30/9/2029	8,716,467	0.22
USD 5,550,000	Republic of South Africa Government International Bond 5.875% 22/6/2030 ^A	5,951,376	0.15
USD 3,150,000	Republic of South Africa Government International Bond 6.25% 8/3/2041	3,185,957	0.08
USD 4,350,000	Republic of South Africa Government International Bond 5.375% 24/7/2044	3,963,774	0.10
USD 4,150,000	Republic of South Africa Government International Bond 5.00% 12/10/2046	3,580,776	0.09
USD 6,000,000	Republic of South Africa Government International Bond 5.65% 27/9/2047	5,532,825	0.14
USD 2,450,000	Republic of South Africa Government International Bond 6.30% 22/6/2048 ^A	2,409,943	0.06
USD 12,150,000	Republic of South Africa Government International Bond 5.75% 30/9/2049	11,216,212	0.28
USD 3,950,000	Transnet SOC Ltd RegS 4.00% 26/7/2022	4,036,071	0.10
		101,856,409	2.54

Electricity
 SA Bonds
 Transport

The Rulers of the World



“The pandemic represents a rare but narrow window of opportunity to reflect, reimagine, and reset our world.”

Klaus Schwab

Founder and Executive Chairman, World Economic Forum





The Rulers of the World

THE GREAT > RESET

There is an urgent need for global stakeholders to cooperate in simultaneously managing the direct consequences of the COVID-19 crisis. To improve the state of the world, the **World Economic Forum** is starting The Great Reset initiative.

The Rulers of the World

Our Partners


World Economic Forum Partners are leading global companies developing solutions to the world's greatest challenges. They are the driving force behind the Forum's programmes.

Our Partners engage in Forum Platforms to shape the future, accessing networks and experts to ensure strategic decision-making on the most pressing world issues.


The logo for the World Economic Forum, featuring the words "WORLD ECONOMIC FORUM" in a sans-serif font, with a blue circular arc partially encircling the text.

WORLD
ECONOMIC
FORUM

WEF PARTNERS




WEF PARTNERS





WORLD
ECONOMIC
FORUM



**Vaccinate the whole
world to end
pandemic**

Antonio Guterres

UN Chief at Davos

14 January 2022


WORLD
ECONOMIC
FORUM



World Health
Organization

Conflicts of Interests?

Top 20 contributors to WHO (2020 - 2021, US\$ million)




Germany	17.13%
Bill & Melinda Gates Foundation	9.39%
United States	

World Health Organisation Funding: Conflicts of Interests



Top 20 contributors to the Programme budget 2018 (US\$ thousands)



Top 20 contributors to the WHO Programme budget 2018 (US\$ thousands)

Image: World Health Organization



World Health Organization

BILL & MELINDA GATES foundation

Contribution 10.8% of WHO budget

\$455 million



\$389 million

Contribution 8.8% of WHO budget

World Health Organisation Funding: Conflicts of Interests



World Health
Organization

Total Contributions:

Country/ Foundation	Total Contribution	Percentage
USA	\$863 million	19.6%
Gates Foundation/ Gavi	\$844 million	18.6%

Top 20 contributors to the WHO for the 2018/2019 biennium


Contributor	Funding received US\$ million
United States of America	853
United Kingdom of Great Britain and Northern Ireland	464
Bill & Melinda Gates Foundation	455
GAVI Alliance	389
Germany	359
UN Office for the Coordination of Humanitarian Affairs (UNOCHA)	286
Japan	234
European Commission	213
Rotary International	168
National Philanthropic Trust	116
UN Central Emergency Response	100
Kuwait	95
World Bank	95
Norway	93
China	89
Canada	87
Sweden	87
Republic of Korea	72
Australia	71
France	71

World Health Organisation Funding: Conflicts of Interests



Top 10 voluntary contributors (specified)

Financial Year (2018-19)



Funding source:

Flexible funding: 94%

Voluntary contributions – specified: 6%

Of the total voluntary contributions specified, 88% were from 10 contributors (shown beside)



CONTRIBUTORS

Period 2020 - 2021

WHO Contributors	Amount(Percentage)	WHO Contributors	Amount(Percentage)	
Bill and Melinda Gates Foundation	\$751M(9.39%)	Johnson & Johnson	\$45 000	*
* GAVI Alliance	\$432M(6.43%)	Johnson & Johnson Companies Contribution Fund	\$495 000	*
* Wellcome Trust	\$7.5M(0.12%)	Gilead Sciences Inc.	\$5.3M(0.08%)	*
World Bank	\$158.1M(2.54%)	Merck & Co.	\$277 028(0.04%)	*
* COVID-19 Solidarity Fund	\$85.8M(1.38%)	GlaxoSmithKline	\$2M(0.03%)	*
United Nations Development Fund (UNDP)	\$85.6M(1.38%)	Sanofi-Aventis	\$10.8M(0.17%)	*
CDC Foundation	\$4.8M(0.07%)	Bayer AG	0.07%	
Gates Ventures	\$218 000	Bristol-Myers Squibb	\$143 236	
* Path Vaccine Solutions	\$92 568	Hoffman-La Roche	\$4 435 165	
National Institutes of Health (USA)	\$688 000	Novartis	\$1.6M(0.03%)	*
* Program for Appropriate Technology in Health (PATH)	\$972 000(0.02%)	Sandoz AG	\$93 458	*
* Rockefeller Foundation	\$5.6M0.09%	Eisai Co. Ltd	\$451 426	
Open Society Foundations	\$265 132	Ely Lilly & Foundation		
Clinton Health Access Initiative	\$1.2M(0.02%)			
Care International				
Sabin Vaccine Institute				

Voluntary contributions by fund and contributor

Contributor	(2021)	(2020)	(2019)
Bill & Melinda Gates Foundation	\$375 597 694	\$375 546 744	\$226 337 804
GAVI Alliance	\$244 540 452	\$187 080 008	\$230 120 648
CDC Foundation	\$1 858 347	\$2 197 194	\$2 844 154
Clinton Health Access Initiative	\$856 492	\$444 021	\$402 343
Rockefeller Foundation	\$750 000	\$3 906 800	\$2 514 994
Grand Challenges Canada (BMGF)			
Gates Ventures, LLC	\$218 000	\$310 750	
Open Society Foundations	\$265 000	\$240 000	\$161 753
Global Antibiotic Research & Development Partnership (GARDP)	\$258 896	\$149 090	
Johnson and Johnson Family of Companies Contribution Fund, Inc.	\$14 957 229	\$600 000	
Johns Hopkins Bloomberg School of Public Health			
Path Vaccine Solutions (PVS)			\$161 753
Program for Appropriate Technology In Health (PATH)	\$972 455		\$345 500
Wellcome Trust	\$5 574 180		
Global Fund to Fight AIDS, Tuberculosis and Malaria	\$29 700 000	\$17 745 189	\$15 718 411
International Vaccine Institute (IVI)	\$317 000	\$60 000	
UNITAID	\$33 519 000	\$18 308 869	\$20 296 997
World Bank	\$38 735 962	\$93 592 671	\$74 005 754
World Organisation for Animal Health (OIE)	\$107 502		
Population Action International (PAI)	\$14 194	\$287 251	\$370 000
Rotary International	\$84 661 438	\$89 162 889	\$86 559 824

WHO Funding

**80% from voluntary
contributions**

**18% from assessed
contribution**

**45% voluntary
contributions (2018
– 2019) from Bill
and Melinda Gates
Foundation**

**Fully invested in
Covid Industry**

Voluntary contributions by fund and contributor

Contributor	(2021)	(2020)	(2019)
Population Services International (PSI)	\$494 725		
Foundation for Innovative New Diagnostics (FIND)	860 352		
United Nations Foundation (UNF) Foundation	3 051 373	125 153 947	
United Nations Population Fund (UNFPA)	\$21 116		\$8 859 001
United Nations Children's Fund (UNICEF)	21 798 361		
United Nations Office for the Coordination of Humanitarian Affairs (UNOCHA)	19 142 097		
Joint United Nations Programme on HIV/AIDS (UNAIDS)	\$14 776	7 952 119	7 391 637
Food and Agriculture Organization (FAO)			327 000

Contributor	(2021)	(2020)	(2019)
London School of Hygiene and Tropical Medicine	\$10 596		37 534
Harvard School of Public Health			162 539
Imperial College of Science, Technology and Medicine	\$328 000		
King's College London	\$127 000		
University of Oxford	\$197 000		



SEVENTY-FIFTH WORLD HEALTH ASSEMBLY
Provisional agenda item 22.1

A75/INF.J5
25 April 2022

Voluntary contributions by fund and contributor


World Health Organization – Voluntary contributions, by fund and by contributor GENERAL FUND

Contributor	(2021)	(2020)	(2019)
Johnson & Johnson		\$150 000	
Hoffmann-La Roche and Co., Ltd.	\$4 435 165	\$4 881 140	\$6 232 482
Eisai Co., Ltd	\$451 426	\$130 000	\$130 000
Bayer AG	\$162 970	\$1 125 989	\$1 864 181
Sinovac Biotech Ltd.	\$60 480	\$91 926	
Medimmune	\$705 594	554 675	\$577 082
Merck & Co., Inc.	\$29 357 680	\$2 009 276	\$1 214 156
Novartis	\$975 248	\$499 690	\$500 000
Sanofi Pasteur	\$10 588 299	\$7 586 478	\$8 096 740
Sanofi-Aventis	\$6 422 239	\$3 788 709	\$4 424 320
SK Bioscience	\$141 119	\$110 935	\$115 416
GlaxoSmithKline (GSK)	\$399 400	\$6 790 490	
Gilead Sciences Inc.	\$200 688	\$2 107 450	\$2 452 100
Bristol-Myers Squibb			\$286 000



World Health
Organization


PIP CONTRIBUTIONS





World Health
Organization





ALL IN-KIND / SERVICE CONTRIBUTORS



World Health Organisation: Big Pharma Influence

 World Health Organization	HOME	OUR WORK	BUDGET & FINANCING	REGIONS	CONTRIBUTORS	WHO		 2020-21 
Total In-Kind – Medical supplies and materials Contributions by Contributors 								
United Arab Emirates								10,376K
Johnson and Johnson Family of Companies Contribution Fund, Inc.								10,114K
Merck & Co., Inc.								9,438K
GlaxoSmithKline (GSK)								8,204K
Republic of Korea								5,990K
Novartis								4,796K
Eisai Co., Ltd.								857,684
Johnson & Johnson Consumer Health								760,630
Kobe Group (Hyogo Prefecture Kobe Chamber of Commerce and Industry and Kobe Steel, Ltd.)								674,836
Gilead Sciences Inc.								466,538
Bayer AG								416,873
Cipla Health Ltd.								200,000
Vital Strategies								81,486
EMS S.A. Brazil								37,762
Fondation d'Entreprise Sanofi Espoir								15,586
Chemo Iberica S.A, Spain								1,092
Total								52,431K

World Health Organisation: Big Pharma Influence

 World Health Organization		HOME	OUR WORK	BUDGET & FINANCING	REGIONS	CONTRIBUTORS	WHO		 2018-19
Total In-Kind – Medical supplies and materials Contributions by Contributors 									
Merck & Co., Inc.	35,413K								
GlaxoSmithKline (GSK)	30,862K								
Johnson and Johnson Family of Companies Contribution Fund, Inc.	14,239K								
Eisai Co., Ltd.	10,733K								
Novartis	7,496K								
Gilead Sciences Inc.	1,405K								
Kobe Group (Hyogo Prefecture Kobe Chamber of Commerce and Industry and Kobe Steel, Ltd.)	674,836								
Fondation d'Entreprise Sanofi Espoir	556,878								
Bayer AG	173,974								
Switzerland	77,517								
Total	101,630K								



World Health
Organization

Big Pharma Conflicts of Interests

WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics 2004

Prof. Karl Nicholson, Member of The European Scientific Working Group on Influenza (ESWI), **Prof. Frederick Hayden**, University of Virginia, **Dr. Arnold Monto**, University of Michigan


Prof Nicholson is on the **Roche** pharmaceutical Company Payroll. He conducted a randomised controlled trial on oseltamivir (Tamiflu) supported by **Roche** and also received travel sponsorship and honorariums from **GlaxoSmithKline and Roche** for consultancy work and speaking at international respiratory and infectious diseases symposiums

Prof Hayden paid by **Roche** for lectures and consultancy work for the company at the time the guidance was produced and published, also received payments from **GlaxoSmithKline** for consultancy and lecturing until 2002. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE) and Board of Wellcome Trust

Prof Monto received honorariums, consultancy fees, and research support from **GSK, Novartis, Roche, Baxter and Sanofi, MedImmune**, consultancy fees and research (GlaxoSmithKline, \$3000 speakers fees in 2009) and also research funding from ViroPharma.



Prof. Karl Nicholson



Prof. Fred Hayden



Dr. Arnold Monto



World Health
Organization

&

ESWI

...scientists fighting influenza

Sponsors





World Health
Organization

Big Pharma Conflicts of Interests

Influenza Pandemic Plan: The Role of WHO and Guidelines for National and Regional Planning

R Snacken, J Wood, L R Haaheim, A P Kendal, G J Ligthart, and D Lavanchy

This document was prepared for the World Health Organization (WHO), in collaboration with the European Scientific Working Group on Influenza (ESWI)(1999).

Dr. René Snacken of the Belgian Ministry of Public Health, WHO Division of Viral Diseases wrote about studies involving neuraminidase inhibitors for a **Roche promotional booklet**

Dr Daniel Lavanchy, **appeared at a Roche sponsored symposium in 1998** while employed at WHO Division of Viral Diseases.

Professor Abe Osterhaus, ESWI Chairman, conducted a **randomised controlled trial on oseltamivir (Tamiflu) supported by Roche**. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE)



World Health
Organization

&

ESWI

...scientists fighting influenza

Sponsors



AstraZeneca

Johnson & Johnson

NOVARTIS

sanofi

Baxter

MedImmune



VIATRIS

The Corporatization of the WHO: A Question of Independence?



COVID-19 Solidarity Response Fund

FUND SUPPORTERS





Dr Tedros Adhanom Ghebreyesus Global Elite “Prostitute”



Tedros Adhanom Ghebreyesus: “Prostituting himself”



World Health
Organization



The Global Fund (2009 to 2011)



The High Level
Taskforce on
Innovative
International
Financing for
Health Systems



IHME

Institute for Health Metrics and Evaluation



Harvard School
of Public Health



Fig. Bill Gates and Tedros Adhanom Gherbreyesus

Director-General Tedros Adhanom Ghebreyesus is in the WHO to do Bill Gates' bidding

The Tigray People's Liberation Front (TPLF) and Dr Tedros Adhanom Ghebreyesus

Table: The United States has classified the TPFL as a Tier III terrorist organization.

199008020002	1990-08-02	Ethiopia	Kobo district	Tigray Peoples Liberation Front (TPLF)	17	0	Religious Figures/Institutions	Sub-Saharan Africa	Armed Assault	Firearms
198802180001	1988-02-18	Ethiopia	Unknown	Tigray Peoples Liberation Front (TPLF)	0	0	Private Citizens & Property,NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Firearms
198410190003	1984-10-19	Ethiopia	Lalibela	Tigray Peoples Liberation Front (TPLF)	200	200	Private Citizens & Property	Sub-Saharan Africa	Hostage Taking (Barricade Incident)	Unknown
198308030001	1983-08-03	Ethiopia	Jari	Tigray Peoples Liberation Front (TPLF)	0	0	NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Unknown
198304200006	1983-04-20	Ethiopia	Korem	Tigray Peoples Liberation Front (TPLF)	Unknown	Unknown	NGO,NGO,NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Unknown
197905020020	1979-05-02	Ethiopia	Workamba	Tigray Peoples Liberation Front (TPLF)	100	0	Private Citizens & Property	Sub-Saharan Africa	Unknown	Unknown
197905020019	1979-05-02	Ethiopia	Aksum	Tigray Peoples Liberation Front (TPLF)	Unknown	Unknown	Private Citizens & Property	Sub-Saharan Africa	Armed Assault	Unknown,Unknown



Dr Tedros Adhanom Ghebreyesus

* listed in the U.S. Homeland Security Global Terrorism Database

Positions Held:

Executive Member of the Tigray People's Liberation Front

Ethiopian Minister of Foreign Affairs

Ethiopian Minister of Federal Ministry of Health

<https://vaccineimpact.com/2020/is-w-h-o-director-tedros-a-terrorist-global-ties-to-bill-gates-clinton-foundation-dr-fauci-china-and-genocide/>

https://www.uscis.gov/sites/default/files/USCIS/Laws/TRIG/2014_Implementation_of_New_Discretionary_Exemption_for_Activities_or_Associations_Relating_to_TPLF.pdf



South African Government ✓



1h • 🌐

[#UbuntuAwards2022](#) | WHO Director-General @DrTedros Adhanom Ghebreyesus was surprised with the Special [#UbuntuHumanitarian](#) Award. Dr Ghebreyesus is currently in SA to discuss progress in making Africa self-sufficient in the production of [#COVID19](#) vaccines & related treatments.



WHO's Dr Maria D. Van Kerkhove: "Globalist Hack and Elitist Puppet"



**Imperial College
London**

Prof Neil Ferguson Senior Research Fellow
Honorary Lecturer



JPMORGAN CHASE & CO. Rockefeller Brothers Fund
philanthropy for an Interdependent World

Google.org facebook. Eisai STATE STREET

**COVID-19 Solidarity
Response Fund**

Pfizer The Pfizer Foundation
Baxter International Foundation
MSD INVENTING FOR LIFE

gsk Johnson & Johnson GE Foundation

THE WORLD BANK
IBRD • IDA

Bloomberg Philanthropies INSTITUT PASTEUR

Post-Doctoral Fellow

LONDON SCHOOL of
HYGIENE & TROPICAL
MEDICINE

PhD Degree



Dr Maria D. Van Kerkhove
COVID-19 Technical Lead of the World Health
Organization (WHO)

CONSIZE
CONSORTIUM FOR THE STANDARDIZATION
OF INFLUENZA SEROEPIDEMIOLOGY

DFID Department for
International
Development

UKRI Medical
Research
Council



**Stanford
MEDICINE**

Masters Degree

CORNELL UNIVERSITY
FOUNDED A.D. 1865

Undergraduate Degree

**BILL & MELINDA
GATES foundation**

NIH NIH
Fogarty National Institutes
of Health



WHO Dr Maria D. Van Kerkhove: “Globalist Hack and Elitist Puppet”

Imperial College
London



Home Publications

Dr Maria D Van Kerkhove

/// Faculty of Medicine, School of Public Health

Honorary Lecturer

▪ Publications



FILTER

https://www.imperial.ac.uk/people/m.vankerkhove/publications.html?respub-action=search.html&id=00567652&limit=30&keywords=&iminyear=2002&imaxyear=2019&itypes=Book%2CBook+chapter%2CConference+paper%2CJournal+article%2COther%2CPatent%2CPoster%2CReport%2CScholarly+edition%2CSoftware%2CThesis+dissertation%2CWorking+paper&_type=on&type=Book&type=Book+chapter&type=Conference+paper&type=Journal+article&type=Other&type=Patent&type=Poster&type=Report&type=Scholarly+edition&type=Software&type=Thesis+dissertation&type=Working+paper&minyear=2002&maxyear=2019&page=1&person=true


WHO's Dr Maria D. Van Kerkhove: "Globalist Hack and Elitist Puppet"

virt BETA

Search 7500+ events

SUBMIT YOUR EVENT

[virt Top Picks](#) [This Week](#) [Past Events](#) [virt Africa](#) [virt India](#)



Dr Maria Van Kerkhove
TECHNICAL LEAD COVID-19
WHO Health Emergencies Programme

Centre for Mathematical Modelling of Infectious Diseases Annual Lecture 2021 with Dr Maria Van Kerkhove

London School of Hygiene and Tropical Medicine

Past Event

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Alejandro Cravioto (Chair)	Universidad Nacional Autónoma de México, Puerto Vallarta, Mexico	Bill & Melinda Gates Foundation. Wellcome Trust. Chief Scientific Officer of International Vaccine Institute (IVI). Executive Director. International Centre for Diarrhoeal Disease Research (icddr, USAID, NIH. CDC. Global Fund)
Dr Hanna Nohynek (Vice-Chair)	Chief Physician, Finnish Institute for Health and Welfare (Thl), Helsinki, Finland	Bill & Melinda Gates Foundation. PATH. Oxford University on ComCov studies. Grants from EU Commission. Expert advisor to European Medicines Agency. Honoraria for GSK and Pfizer. Finnish Institute for Health and Welfare receives funding from Sanofi Pasteur. GlaxoSmithKline.
Prof Shabir Madhi	Univ of the Witwatersrand, Johannesburg, SA	Funding from Pfizer, Minervax, GlaxoSmithKline, Novavax. Bill & Melinda Gates Foundation. International Vaccine Institute (IVI) Scientific Advisory Committee. BMGF Global Health Scientific Advisory Committee. Advisor to the Pfizer Group B streptococcal (GBS) vaccine program. Member of the Data and Safety Monitoring Board (DSMB) of GSK and Janssen. Chair of the DSMB of CAPRISA. Clinical-Regulatory Advisory Board of CureVac for Covid-19 vaccine. National Principal Investigator, AstraZeneca ChAdOx-nCoV19 vaccine. Wits Health Consortium funded by Novartis, GSK, Medimmune, Novovax. Mitsubishi. Merck (MSD), Novavax.
Prof Peter McIntyre	Dunedin School of Medicine, Univ of Otago, Dunedin, New Zealand	Member of the DSMB for the Novavax Covid-19 vaccine. Member of the New Zealand Scientific and TAG on COVID-19 vaccines. Deputy Director of Australia's National Centre for Immunisation Research and Surveillance of Vaccine-Preventable Diseases (NCIRS). investigator on Wellcome Trust grant.

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Anthony Scott	London School of Hygiene and Tropical Medicine. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya	Funding from Wellcome Trust, Bill and Melinda Gates Foundation, National Institute for Health Research (NIHR). Worked with WHO and GAVI on vaccines. Joint Committee on Vaccination and Immunisation (JCVI) Board member. Director of the NIHR Health Protection Research Unit in Immunisation. Advisor to UK Health Security Agency. World Bank International Vaccines Task Force.
Prof Kathleen M. Neuzil	Director, Univ of Maryland School of Medicine, Baltimore, USA	Funding from Pfizer and NIH. Bill and Melinda Gates Foundation-funded Typhoid Vaccine Acceleration Consortium (2016-2021). CDC Advisory Committee on Immunization. Serum Institute of India, Ltd. Co-chair of the NIH COVID Vaccine Prevention Network. Univ of Maryland funding from GSK, Merck, Nosocomial Vaccine Corporation, ICON Clinical Research. Previous employment: PATH. Studied at Johns Hopkins University School of Medicine. Member on the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. Associate Editor of the journal Vaccine
Prof Kim Mulholland	Professor of Child Health and Vaccinology, London School of Hygiene and Tropical Medicine. Murdoch Children's Research Institute (MCRI), Melbourne, Australia	Safety Monitoring Committee from the Novavax Covid-19 Vaccine. Novavax Maternal RSV immunization project. PCV13 vaccination project on adult pneumonia in Mongolia funded by Pfizer. Principal Investigator in pneumococcal vaccine trials 1 and 2 funded by the Bill and Melinda Gates Foundation. Member of Gates Foundation DeCoDe Committee to review CHAMPS. Receives funding from GAVI.
Prof Noni MacDonald	Paediatrics, Dalhousie University, Halifax, Canada	Funding from Bill and Melinda Gates Foundation, WHO (Consultancy). Academic Committee Member of Leger, Canada. Board member of International Vaccine Institute. Member of the SAGE Working Group on Vaccine Hesitancy

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Rakesh Aggarwal	Director, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India	MSc from London School of Hygiene and Tropical Medicine
Dr Jaleela Jawad	Consultant, Ministry of Health Manama, Bahrain	CDC USA
Dr Sonali Kochhar	Assoc Prof, Univ of Washington, Seattle, USA	Funding from Bill & Melinda Gates Foundation, Wellcome Trust.
Prof Punnee Pitisuttithum	Mahidol University, Bangkok, Thailand	Safety Monitoring Committee for the U.S. Military HIV Research Program. Principal investigator Safety of Tri Fluvac influenza vaccine and MSD-funded 9vHPV vaccine.
Dr Folake Olayinka	Immunization Team Leader, USAID (Public Health Institute STAR Fellow). Washington, USA	Advisor to the WHO-AFRO Regional Immunization Technical Advisory Group.
Dr Ezzeddine Mohsni	Programme Essaha Aziza, European Union Tunis, Tunisia	Funding from Bill and Melinda Gates Foundation, Gavi and WHO.
Dr Ilesh V. Jani	Director General, National Institute of Health, Marracuene, Mozambique	Funding from CEPI and Bill and Melinda Gates Foundation, Janssen Vaccines & Prevention B.V., US National Institutes of Health (NIH), the HIV Vaccine Trial Network (HVTN). Grant/research support from WHO
Prof Andrew Pollard (former member)	Director of the Oxford Vaccine Group	Chief investigator for the Oxford-AstraZeneca COVID-19 vaccine clinical trials. Chair, Joint Committee on Vaccination and Immunisation (JCVI), Chair Scientific Advisory Group on Vaccines at the European Medicines Agency, National Institute for Health and Care Excellence (NICE, UK). Senior Advisor to the Medicines and Healthcare Products Regulatory Agency (MHRA) Panel, Advisor to the European Medicine Agency (EMA). Lead developer of the Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK. Funding from Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI),

[Health Topics](#) ▾[Countries](#) ▾[Newsroom](#) ▾[Emergencies](#) ▾[Data](#) ▾[About Us](#) ▾

Strategic Advisory Group of Experts on Immunization, Vaccines and Biologicals (SAGE)



Bernard Fritzell, M.D., M.P.H. former Vice-President, International Scientific and Clinical Affairs, Pfizer Vaccines Research



Barney S. Graham, M.D., PhD Senior Investigator at the Vaccine Research Center, NIAID, NIH



Ruth Karron, M.D. CDC Advisory Committee on Immunization Practices. FDA Vaccine and Related Biological Products Advisory Committee



David C. Kaslow, M.D. Vice President, Essential Medicines, and Head, PATH's Center for Vaccine Innovation and Access Vice President and Head of Vaccines Project Leadership and Management at Merck Research Laboratories National Institute of Allergy and Infectious Diseases (NIAID)



Jerome H. Kim, M.D., Director General of the International Vaccine Institute (IVI) funded by Bill and Melinda Gates Foundation.



Prof. Shabir Madhi, Prof Vaccinology, Wits Univ. Head of SA AstraZeneca ChAdOx1 Trial, Chair of the National Advisory Group for Immunization in South Africa and on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation Global Health Program.

Gates Foundation: Decade of Vaccines Collaboration

Global Health Leaders Launch Decade of Vaccines Collaboration | Bill & Melinda Gates Foundation

Media contact

Phone:

[206-709-3400](tel:206-709-3400) ↗

Mail:

media@gatesfoundation.org →



Decade of Vaccines

Magdalena Robert

Phone: +34 93 227 1806

The Council comprises of the Director-General of the WHO, the Director of NIAID, the Director of UNICEF, the President of Gates Foundation Global Health, and the Chair of the African Malaria Alliance

NEW YORK -- The [World Health Organization](#) (WHO), [UNICEF](#), the [National Institute of Allergy and Infectious Diseases](#) (NIAID) and the Bill & Melinda Gates Foundation have announced a collaboration to increase coordination across the international vaccine community and create a Global Vaccine Action Plan. This plan will build on the successes of current work to achieve key milestones in the discovery, development and delivery of lifesaving vaccines to the most vulnerable populations in the poorest countries over the next decade.

WHO and Criminals Inc. and the Global Vaccine Action Plan



World Health
Organization

Health Topics ▾

Countries ▾

Newsroom ▾

Emergencies ▾

Data ▾

About Us ▾

<https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/global-vaccine-action-plan>

Global Vaccine Action Plan publication

The Global Vaccine Action Plan (GVAP) — endorsed by the 194 Member States of the World Health Assembly in May 2012 — is a framework to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.

GVAP was the product of the DoV Collaboration, an unprecedented effort that brought together development, health and immunization experts and stakeholders. The leadership of the Bill & Melinda Gates Foundation, GAVI Alliance, UNICEF, United States National Institute of Allergies and Infectious Diseases and WHO, along with all partners – governments and elected officials, health professionals, academia, manufacturers, global agencies, development partners, civil society, media and the private sector – are committed to achieving the ambitious goals of the GVAP. Many more are expected to add their support in the future as the plan is translated and implemented at the country and regional levels.

BILL & MELINDA
GATES foundation



14 JUNE 2020

**Global Vaccine
Action Plan
Monitoring,
Evaluation &
Accountability:
Secretariat
Annual...**

Download

Read More



Conflicts of Interest

Bill Gates influence invests Big in Big Pharma and Vaccine Industry

BILL & MELINDA
GATES *foundation*

June 4, 2020

**Bill and Melinda Gates
Foundation pledges \$3 billion to
GAVI, The Vaccine Alliance, to
protect the next generation with
lifesaving vaccines**

Whistleblower exposes WHO Corruption

On Vaccines and Immunity

- GAVI operates like a Vaccine Cartel, controlling the coronavirus response of nations. They have 'Total Immunity' from prosecution.
- Bill Gates funded GAVI (Global Alliance for Vaccines and Immunisation) has created a system called "Performance based funding" whereby they financially punish nations based on their compliance or non-compliance to vaccination programs.
- World Bank and GAVI (BMGF funded) created the IFFM International Financial Facility for Immunization. They have an agreement that GAVI receives money from countries. GAVI dictates vaccine policies for countries and countries pay them – HUGE CONFLICT OF INTEREST




Dr Astrid Stuckelberger
WHO Insider and Whistleblower

Vaccine Alliance: Major Conflicts of Interest

Gavi Board Chair: José Manuel Barroso



Fig. José Manuel Barroso, GAVI Chair



The WEF and Major Conflicts of Interest

Gavi Board Chair: José Manuel Barroso



José Manuel Barroso, GAVI Chair, WEF (May, 10, 2010)



Fig. José Manuel Barroso, Klaus Schwab in deep conversation at the World Economic Forum on Europe held in Brussels, Belgium, May 10, 2010.

Vaccine Alliance: Major Conflicts of Interest

Gavi Board Member: Margaret Ann Hamburg



Margaret Ann Hamburg



Assistant Secretary



National Institute of Allergy and Infectious Diseases



Assistant Director



**U.S. FOOD & DRUG
ADMINISTRATION**

FDA Commissioner

BILL & MELINDA GATES foundation

Member of the
Global Health
Scientific Advisory
Committee

CEPI

Chair of the Joint
Coordinating Group



The ROCKEFELLER FOUNDATION

Board of Trustees Member

THE ROCKEFELLER UNIVERSITY

Science for the benefit of humanity



HENRY SCHEIN®

Board Director

U.S. distributor of flu vaccines and dental amalgam



Anylam®
PHARMACEUTICALS

Member of the Board of Directors
RNAi therapeutics

SANOFI

10% share



NOVARTIS

\$545M sharevalue



wellcome

Member of the Strategic Advisory Board on
Vaccines and Drug-resistant Infections



NTI
BUILDING A SAFER WORLD

Senior Scientist
Nuclear Threat Initiative



AAAS
ADVANCING SCIENCE, SERVING SOCIETY

Chair of the Board



CSIS | CENTER FOR STRATEGIC & INTERNATIONAL STUDIES

senior fellow

**COUNCIL on
FOREIGN
RELATIONS**

Member of the Board of
Directors, Independent Task
Force on Improving (Covid)
Pandemic Preparedness, 2020



Harvard University
Member of the
Board of Fellows

Renaissance



Peter Fitzhugh Brown
Hamburg's Husband,
CEO Renaissance



TITAN®
PHARMACEUTICALS

61,913 shares
December 2015

Probuphine

Johnson & Johnson



MERCK



Abbott

medco®

Intergovernmental Negotiating Body (INB)

Conflicts of Interest



**World Health
Organization**

Intergovernmental Negotiating Body



Ms Precious Matsoso

(South Africa)

- * Member of the Executive Board of World Health Organisation**
- * Director General of the National Department of Health, SA**

Co-Chairs of Intergovernmental Negotiating Body (INB)

(February 24, 2022)



Dr Roland Driece

(Netherlands)

- * Chair of the Global Health Security Agenda**
- * Vice-President, Conference of the Parties representing the European Region**

The INB was established to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response focused on a new revised International Health Regulations

International Health Regulations Committee (IHR)

Conflicts of Interest

International Health Regulations (IHR) Committee



Prof Arnold Monto,
University of Michigan

- * Acting Chair of the FDA's Vaccines and Related Biological Products Advisory Committee

- * Consultant for GSK, Novartis, Roche, Baxter and Sanofi

- * His research unit funding from Sanofi Pasteur for influenza vaccine trial conducted in 2007-2008



Prof Neil M. Ferguson
Imperial College, London

- * Scientific Advisory Group for Emergencies (SAGE)(UK)
- * Head of International Health Regulations (IHR) (2005) Emergency Steering Committee

- * Consultant for Roche, Novartis, Baxter and GSK Biologicals

- * Funding from Sanofi, Janssen, Thermo-Fischer Scientific

- * Funding from Bill and Melinda Gates Foundation, Wellcome Trust, CEPI, GAVI,



Dr Nancy J. Cox

- * Director of CDC's World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza

- * Past Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC)



Prof Maria Zambon
Deputy Director Public Health England

- * Member UK Scientific Advisory Group for Emergencies (SAGE)

- * Deputy Director Public Health England

- * Member of International Health Regulations (IHR) (2005) Steering Committee

- * Co-Director of the NIHR Respiratory Health Protection Unit with Imperial College London

- * UK Health Protection Agency Centre for Infection (Zambon Lab) funding sources, Sanofi, Novartis, CSL, Baxter and GSK.

- * Publications funding: Bill and Melinda Gates Foundation Wellcome Trust

- * Support of Jeremy J. Farrar (Wellcome Trust) and World Health Organization




Masato Tashiro

- * Director, WHO Collaborating Centre for Reference and Research on Influenza

- * WHO Essential Reference Laboratory of GISRS

Prof Neil Ferguson: Covid Modeller and Major Conflicts of Interest



SOUTH AFRICA INC.



World Health
Organization

“LAPDOG”

Cyril Ramaphosa: SA Elite joins the Global Cabal



Prof Salim Abdool Karim: A 'Global Élite' Puppet

BILL & MELINDA GATES foundation
Scientific Advisor

CAPRISA
CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA
Director and co-Founder

saMRC
advancing life
Former President and CEO

COLUMBIA
MAILMAN SCHOOL OF PUBLIC HEALTH
HARVARD UNIVERSITY
CORNELL UNIVERSITY
FOUNDED A.D. 1865
Adjunct Professor

THE ROYAL SOCIETY
Fellow of the Royal Society (FRS)

MRC HIV-TB Pathogenesis and Treatment Director


MIT
Massachusetts Institute of Technology
Associate

PEPFAR
U.S. President's Emergency Plan for AIDS Relief
Advisor

mBio
Editorial Board

iavi
International AIDS Vaccine Initiative
Scientific Advisory Committee

The Global Fund
To Fight AIDS, Tuberculosis and Malaria
Professor of Global Health



Prof Salim Abdool Karim

South African Ministerial Advisory Committee on COVID-19 Over-Archiving Chair
Republic of South Africa

MERCK
Consultant

UNAIDS
Chair: UNAIDS Scientific Expert Panel

NIH
NIAID
USAID
FROM THE AMERICAN PEOPLE
EU
Funders



World Health Organization

WHO Science Council HIV and Hepatitis Scientific and Technical Advisory Group
WHO HIV-TB Task Force Chair of the Scientific and Technical Advisory Group for Reproductive Health

The NEW ENGLAND JOURNAL of MEDICINE
Editorial Board

UNIVERSITY OF KWAZULU-NATAL
INYUVESI YAKWAZULU-NATALI
Pro-Vice-Chancellor

POPULATION COUNCIL
Ideas. Evidence. Impact.
Board Member

THE LANCET Global Health
THE LANCET HIV
Editorial Board

THE LANCET COVID-19 COMMISSION
Commissioner

The ROCKEFELLER FOUNDATION
Scholarship, 1987

LONDON SCHOOL of HYGIENE & TROPICAL MEDICINE
Masters Scholarship, 1987

CDC
CENTERS FOR DISEASE CONTROL AND PREVENTION
Studied, 1988

19 09 LIVE



Karim
gets his
reward?


WORLD HEALTH ORGANIZATION

PROF. SALIM ABDOOL KARIM

WHO
SCIENCE PANEL



WATCHING eNCA ON DSTV CHANNEL 403 PLEASE SEND PICS AND VIDEOS TO pictures@enca.com OR upload.e





University of the Witwatersrand

WITS RHI

Wits Reproductive Health and HIV Institute and Prof Helen Rees

Conflicts of Interest



Founder & Director
of Wits RHI

Donors & Partners



THE AURUM
INSTITUTE




UNIVERSITY OF THE
WITWATERSRAND
JOHANNESBURG



BILL & MELINDA
GATES foundation

\$750million



Prof Glenda Gray (SAMRC): Another “Global Elite Puppet”



Bill Gates and the South African Ministerial Advisory Committee on COVID-19

Researcher	Institution	Role in MAC	Sub Funder	Principal Funder
Prof Salim Abdool Karim	CAPRISA	OVER-ARCHING CHAIR	USAID via Concord WHO TB-HIV task force	Bill and Melinda Gates Foundation (BMGF)
Prof Quraisha Abdool Karim	CAPRISA	Public Health		BMGF
Prof Helen Rees	South African Health Products Regulatory Authority (SAHPRA)	Clinicians	WHO, Co-Chair Ebola Vaccine	BMGF
Prof Lynn Morris	National Institute for Communicable Diseases (NICD)	Pathologists and Laboratory		BMGF
Prof Wolfgang Preiser	National Health Laboratory Service	Pathologists and Laboratory		BMGF
Prof Wendy Stevens	National Health Laboratory Service	Pathologists and Laboratory		BMGF
Prof Shabir Madhi	SAMRC	CHAIR, Public Health	WHO, Consultant	BMGF, Consultant
Prof Glenda Gray	SAMRC	CHAIR, Research	NIH, Wellcome Trust	BMGF
Prof Marc Mendelson	University of Cape Town	CHAIR, Clinicians	WHO	BMGF
Dr Moherndran Archary	University of KwaZulu-Natal	Clinicians		BMGF
Prof Shabir Banoo	Right to Care	Clinicians	WHO	BMGF

UK SAGE Conflicts of Interest

HOW 'INCESTUOUS' CAN IT GET!



Sir Patrick Vallance

- * Chief Scientific Adviser, UK Government (2018 – present)
- * Chair of Scientific Advisory Group for Emergencies (SAGE) (2020 – present)
- * Chair Pandemic Preparedness Partnership (UK), joint public-private-partnership with Gates funded CEPI (2021 – present)
- * Head of UK Vaccine Taskforce (2021 – present)

- * Former President of GlaxoSmithKline (2012-2017)
- * £600,000 shares in GlaxoSmithKline
- * UK government signs coronavirus vaccine deal with GlaxoSmithKline (July 2020)
- * GSK-Gates Foundation partnership (2013) to 'accelerate vaccine research for global health needs



Prof Chris Whitty

- * Chief Medical Officer, UK
- * Executive Board of the World Health Organization
- * Professor of Public and International Health London School of Hygiene and Tropical Medicine (LSHTM)
- * Received £31million in funding from the Bill and Melinda Gates Foundation for malaria research



Prof Jonathan Van-Tam

- * Deputy Medical Officer, UK
- * Chair New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG)
- * UK Vaccine Taskforce advisor
- * Advisor to the World Health Organisation
- * Associate director SmithKline Beecham (now GSK, 2000)
- * Head of Medical Affairs at Roche (2001)
- * Aventis Pasteur MSD UK medical director (2002)

Global Health Security Agenda Architecture



Who We Are

The Panel for a Global Public Health Convention (GPHC) represents an independent coalition of global leaders working to strengthen the world's ability to prevent, prepare, and respond to infectious disease outbreaks before they become widespread pandemics.

The Panel was founded in 2020 in response to the emergence of the COVID-19 pandemic with the aim of bridging critical gaps in the **global public health architecture** and policy frameworks by promulgating a new **global public health treaty** or convention in an effort to ensure another pandemic of such magnitude does not happen again.


Capture of Global Health Security Agenda: WHO

No.	Recommendation	Description
1.	Authorize a Governing Body	Authorize one or more agencies to coordinate pandemic prevention, preparedness, and response globally—across regions, countries, and subnational jurisdictions
2.	Prepare and Respond	Give the global public health system—and its governing agency or agencies—the capability to flexibly and rapidly respond to a range of possible public health security threats and scenarios.
3.	Single Authoritative Source of Information	One agency must be designated to be the singular authoritative source for information, data, and technical assistance and to communicate a clear and compelling message to the world.
4.	Measure Progress	Build the capacity to objectively evaluate countries on their progress in achieving requirements and the capability to remediate identified deficiencies.
5.	Mechanisms to Enhance Compliance and Enforcement With International Agreements	Equip a pandemic prevention, preparedness and response governing body (or bodies) with appropriate enforcement mechanisms. These may include substantial incentives, disincentives for implementation for compliance and/or sanctions for noncompliance.
	Inspectorate function needed - ability to enter a territory for inspection and compliance verification.	<p>Transparency of governments:</p> <ul style="list-style-type: none"> - Immediate and transparent notification of outbreaks - Ongoing data sharing throughout - Acceptance of independent validation <p>Independent monitoring of preparedness and response</p>

Capture of Global Health Security Agenda: WHO

No.	Recommendation	Description
6.	Protect Governance Structure from Political Pressure	The governing body (or bodies) should be autonomous, with the freedom of self-governance and decision-making processes that are resistant to undue political pressures.
7.	Sustainable Funding	<p>Global pandemic prevention agencies must have sovereign control of sustainable financial resources and enduring, annual funding to:</p> <ul style="list-style-type: none"> Lead globally all stages of infectious disease containment—especially prevention-related activities to prepare and respond to outbreaks before they become pandemics. Build within-country public health core capacities. Contingencies for possible emergencies in the future. <p>Financing: combination of compulsory and voluntary member state contributions; taxes on global private industry or international trade; and/or a permanent endowment from philanthropies, private companies and countries.</p>
8.	Ensure Representation and Accountability for All Nations	Ensure the governing framework represents all countries and other relevant nonstate stakeholders and is highly transparent and accountable.
9.	Involve all Parts of Society	At all levels of governance and action, involve multiple sectors, including national governments, the private sector, local governments and civil society.
10.	Ensure Responsibility	Ensure that individual countries understand the threat that infectious disease pandemics pose, take responsibility, are committed to these efforts and agree to fully comply and collaborate for the common good.

Global Health Security Agenda Architecture



Global Health Security Agenda



Private
Sector
Roundtable

Private Sector Roundtable on Global Health Security

Co-Chairs of Private Sector Roundtable (PSRT)



Dr Alan Tennenberg

Chief Medical Officer Global
Public Health, Johnson &
Johnson



Ashling Mulvaney

Vice President, Global Sustainability,
Access to Healthcare, AstraZeneca



Dr. David Barash

Chief Medical Officer and
Executive Director of Global
Health, GE Foundation





H.E. Dr Gro Harlem Brundtland

Co-Chair, GPMB; Former Prime Minister, Norway and Former Director-General, World Health Organization Bilderberger (1983)



Mr Elhadj As Sy

Co-Chair, GPMB, Secretary-General, International Federation of Red Cross and Red Crescent Societies Wellcome Trust



H.E. Dr Diane Gashumba

Minister of Health, Republic of Rwanda



H.E. Sigrid Kaag

Minister for Foreign Trade and Development Cooperation, The Netherlands



Dr Victor Dzau

President, The National Academy of Medicine, USA Director of PepsiCo (2005). Advisor NIH



Dr Chris Elias

President, Global Development Program, Bill & Melinda Gates Foundation, USA



Professor Ilona Kickbusch

Director, Global Health Centre, Graduate Institute of International and Development Studies, Switzerland



H.E. Professor Veronika Skvortsova

Minister of Health, Russian Federation



Sir Jeremy Farrar

Director, Wellcome Trust, UK



Dr Anthony S. Fauci

Director, National Institute of Allergy and Infectious Diseases, USA



Dr Yasuhiro Suzuki

Chief Medical and Global Health Officer, Vice Minister for Health, Ministry of Health, Labour and Welfare, Japan



Dr Jeanette Vega Morales

Chief Medical Innovation and Technology Officer, La Red de Salud UC-Christus, Chile



Ms Henrietta Fore

Executive Director, UNICEF



Dr George F. Gao

Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China



Professor K. VijayRaghavan

Principal Scientific Advisor to the Government of India



Simulation Exercise

A simulation exercise (SimEx) can help develop, assess and test functional capabilities of emergency systems, procedures and mechanisms to be able to respond to outbreaks or public health emergencies.

The video will explain in 4 minutes the SimEx practice as promoted by WHO, including the definition, the different types of SimEx (table top exercise, drill, functional exercise and field/full scale exercise) and available resources.

“Simulation exercises have been identified as a key voluntary instrument in the validation of core capacities under the “Implementation of the International Health Regulations: Draft 5-year draft global strategic plan to improve public health preparedness and response”, which was adopted by the seventy first World Health Assembly. Simulation exercises, along with After Action Reviews, represent the functional assessment of capacities and complement States Parties annual reporting, independent reviews, and joint external evaluations. They play a key role in identifying the strengths and gaps in the development and implementation of IHR capacities and to support countries to assess the operational capability of their national capacity for public health preparedness and response.” – WHO

Simulation exercise calendar

Upcoming

- | | |
|----|--|
| SE | 15 September 2020 to 16 September 2020
Ukraine -Regional EU Chem React 2 field exercise FX Sep.2020 |
| SE | 21 September 2020 to 25 September 2020
South Sudan-Uganda Regional cross border SimEx |
| SE | 21 September 2020 to 25 September 2020
South Sudan-Uganda Regional cross border SimEx |

Bill Gates, WEF, WHO and Covid-19 Simulations



Sponsored by John Hopkins University, World Economic Forum and Bill and Melinda Gates Foundation (BMGF) (October 2019)

Simulates an outbreak of a novel zoonotic coronavirus transmitted from bats to pigs to people that eventually becomes efficiently transmissible from person to person, leading to a severe pandemic. The pathogen and the disease it causes are modeled largely on SARS, but it is more transmissible in the community setting by people with mild symptoms. The pandemic is only stopped in its tracks with the timely vaccination of the entire global population

Gates Foundations Give Johns Hopkins \$20 Million Gift to School of Public Health for Population, Reproductive Health Institute

Dennis O Shea
Phone: 410.516.7160
Email: dro@jhu.edu

Lisbeth Pettengill
School of Public Health
Phone: 410.955.6878
Email: lpetteng@jhsph.edu

BALTIMORE -- The Bill & Melinda Gates Foundations have committed \$20 million to create the Bill & Melinda Gates Institute for Population and Reproductive Health at the Johns Hopkins University School of Public Health.

Bill & Melinda Gates Foundation
☎ 206-709-3400
✉ media@gatesfoundation.org
🐦 follow @gatesfoundation

BILL &
MELINDA
GATES
foundation

WORLD
ECONOMIC
FORUM

 **JOHNS HOPKINS**
BLOOMBERG SCHOOL
of PUBLIC HEALTH

Bill & Melinda Gates Institute for
Population and Reproductive Health

[Home](#)[Leadership](#)[Networks](#)[Resources](#)[News](#)[Calendar](#)[COVID-19](#)

Ukraine -Regional EU Chem React 2 field exercise FX Sep.2020

Region:

European Region

Country:

Ukraine

Date of exercise:

15 September 2020 to 16 September 2020

To event remaining 4 days

Activity Type:

FX

Status:

Planned

Simulation exercise calendar

Upcoming

SE

15 September 2020 to 16 September 2020

[Ukraine -Regional EU Chem React 2 field exercise FX Sep.2020](#)

SE

21 September 2020 to 25 September 2020

[South Sudan-Uganda Regional cross border SimEx](#)



Scott Gottlieb

On the left is the former FDA commissioner in charge of regulating Pfizer. On the right is a current member of the Board of Directors of Pfizer.



Stephen Hahn

On the left is the former FDA commissioner in charge of regulating Moderna. On the right is the current Chief Medical Officer of Flagship Pioneering - the venture capital firm behind Moderna.



James C. Smith

On the left is the CEO of Reuters in charge of informing people about the COVID-19 vaccines. On the right is a current member of the Board of Directors of Pfizer.



Anthony Fauci

On the left is the NIAID Director under the National Institutes of Health. On the right is the funder of bioweapons research on gain of function bat coronaviruses at the Wuhan Institute of Virology.



STOP

THE

WHO

PANDEMIC
ACCORD